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Abstract
Background and Aims Endotoxin/lipopolysaccharide
(LPS) alters gastrointestinal functions. However, little is
known as to whether LPS could change gastric antral
contractility in freely moving conscious animals. We tried
to clarify this problem and the associated mechanisms.
Methods In this study, we recorded intraluminal gastric
pressure waves in freely moving conscious rats by mano-
metric catheter located in the antrum. Area under the
manometric trace was evaluated as motor index (MI).
Results Intraperitoneal injection of LPS at doses of
0.2 mg/kg or more significantly inhibited MI. The inhibi-
tion started immediately after the administration of LPS
and lasted over 1 h. Intraperitoneal injection of IL-1b
potently decreased MI while neither IL-6 nor TNF-a
inhibited gastric motility, suggesting IL-1b specifically
reduced gastric motility. Next, we examined the hypothesis
that endogenous IL-1 mediates the LPS-induced inhibition
of gastric motility. To address the speculation, an IL-1
receptor antagonist (IL-1Ra) was used to block IL-1 sig-
naling. Pretreatment with IL-1Ra at a dose of 20 mg/kg
significantly blocked the inhibition of gastric contractility
by LPS at a dose of 0.2 mg/kg.
Conclusions These results suggest for the first time that
LPS or IL-1b is capable of inhibiting gastric motility in
conscious rats and that endogenously released IL-1 may
mediate the LPS-evoked inhibition of gastric antral
motility. This evidence also led us to speculate that IL-1Ra
may be a therapeutic tool for patients with disturbed gas-
trointestinal functions under septic conditions.
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Abbreviations
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Introduction
Sepsis induces the disturbance of gastrointestinal motility
[1]. A therapeutic approach to improve gastrointestinal
motility could break the intestinal cycle of sepsis and
prevent the development of a sepsis-induced systemic
inflammatory response syndrome and multiple organ fail-
ure [1]. Regrettably, very limited knowledge exists
regarding the pathogenesis of sepsis-induced gastrointes-
tinal motility disturbance [2, 3], and it remains to be fully
elucidated whether there are mechanistically microbial-
mediated alterations in gut motility. Exogenous lipopoly-
saccharide (LPS) from gram-negative bacteria is known to
be a causative factor of sepsis-induced pathophysiological
changes [4].
A number of studies have examined the effect of
endotoxin/LPS on gastrointestinal functions. For example,
Pons et al. [5] have demonstrated that intestinal myoelec-
tric activity was inhibited by intravenous administration of
LPS at a dose of 0.05 mg/kg in conscious fasted rats
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chronically implanted with nichrome electrodes in the
duodenojejunum. With regard to the effect of LPS on
gastric functions, gastric acid secretion and gastric emp-
tying were inhibited by systemic administration of LPS in
conscious animals [6–11]. A couple of studies have
examined the effect of LPS on gastric contractility. In
anesthetized rats, Quintana et al. [12] have demonstrated
that intravenous injection of LPS at a dose of 0.04 mg/kg
by itself failed to change gastric pressure but could inhibit
the stimulated gastric tone induced by 2-deoxy-D-glucose
in urethane-anesthetized rats. Watanabe et al. [13] mea-
sured gastric motility by force transducers in conscious
fasted rats and reported that within 2–3 min after LPS at a
dose of 1 mg/kg injected intravenously, strong repetitive
contraction waves emerged and lasted for 15–20 min. After
that, motility was suppressed for more than 2 h. It was also
reported that a 0.3 mg/kg dose of LPS failed to inhibit
gastric contractility. Thus the dose–response effects of
LPS, and the effects of LPS on gastric motility, i.e., inhi-
bition or stimulation, remain controversial. We therefore
tried to clarify the effects of LPS on gastric contractility




LPS used in the present study was obtained from Esche-
richia coli with the serotype 055:B5 (Sigma Chemical,
USA). IL-1b, TNF-a and IL-6 were purchased from Wako
Pure Chemical Industries, Ltd, Japan. Recombinant human
IL-1 receptor antagonist (IL-1Ra) (anakinra) was pur-
chased from Biovitrum, Sweden. These chemicals were
dissolved in endotoxin-free physiological saline before
injected.
Animal Preparation
Male Sprague–Dawley rats weighing approximately 250 g
were housed under controlled light/dark conditions with
the room temperature regulated at 23–25 C. Rats had free
access to rat chow (solid rat chow, Oriental Yeast Co.,
Tokyo, Japan) and tap water.
Intragastric pressure was detected by manometric
methods as described in recent publications [14, 15]. Under
ether anesthesia, an open-tipped catheter (3-Fr, 1 mm ID;
Atom, Tokyo, Japan) was inserted into the gastric antrum
to measure gastric tone. The catheter was fixed by sutures
at the place of exit from the gastric wall, taken out together
through the abdominal wall, and tunneled through the
subcutaneous to exit at the skin at the back neck. Rats were
maintained in individual cages for approximately 3 days
before the experiments.
Measurement of Gastric Motility and Experimental
Protocols
Conscious fed rats were placed in wire-bottom and non
restraint polycarbonate cages. To avoid biting and allow
free movement, the manometric catheter was passed
through a flexible metal sheath and connected to an infu-
sion swivel (Instech Laboratories, Plymouth Meeting,
USA). The end of the catheter was then connected to a
pressure transducer (TP-400T; Nihon Koden Kogyo,
Tokyo, Japan). Degassed distilled water was continuously
infused at a rate of 1.5 ml/h by a heavy-duty pump
(CVF-3100; Nihon Koden Kogyo). Gastric pressures were
measured and recorded in a Power Lab system (AD
Instruments, Colorado Springs, USA). One hour of stabil-
ization, and measurement of gastric pressure waves was
initiated. Then, the gastric pressure at the basal state was
measured and recorded for 1 h. In the next step, the rats
were removed from their cages to receive intraperitoneal
injections. Rats were anesthetized with ether and received
intraperitoneal injection of each chemical (0.3 ml). After
the administration, rats were returned to the cages again
and the catheter was re-connected to the recording system,
and the intragastric pressure was recorded for 2 h. In a
separate set of experiments, recombinant human IL-1Ra at
a dose of 20 mg/kg (0.3 ml) or saline (0.3 ml) was injected
intraperitoneally under brief ether anesthesia 30 min before
intraperitoneal injection of LPS at a dose of 0.2 mg/kg.
Calculating the Motor Index (MI)
The motor index (MI) was evaluated by area under the
manometric trace (AUT), which was calculated using the
software LabChart v7 (AD instruments, Colorado Springs,
USA). First, MI at the basal state was calculated. Next, the
%MI was determined by calculating as follows: (AUT for
each 1 h period after each intraperitoneal injection of tested
chemicals)/(basal MI) 9 100. In the present experiments,
gastric pressure waves were continuously recorded up to
4 h (2 h for stabilization [1 h] and basal MI [1 h] and 2 h
after tested chemicals). During the process, measurement
was temporally interrupted to inject intraperitoneally tested
solutions. To get the appropriate recordings for the analy-
sis, the data during the recovery period for 5 min was
excluded from later analysis.
Statistical Analysis
For statistical analysis of the data, data were expressed as
means ± SE. Student’s t test was used for comparison of
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%MI between vehicle ? LPS and IL-1Ra ? LPS injec-
tion. The other data were analyzed by one-way ANOVA
followed by Dunnett’s multiple comparison test. Values of
P \ 0.05 were considered statistically significant.
Ethical Considerations
The approval of the Research and Development and Ani-
mal Care committees at the Asahikawa Medical University
was obtained for all studies.
Results
First, we examined the effects of intraperitoneal injection
of LPS on gastric antral motility in freely moving con-
scious rats. As demonstrated in Fig. 1, saline administra-
tion did not affect the intragastric pressure. LPS at a dose
of 20 mg/kg potently suppressed gastric antral contractility
while a 0.002 mg/kg dose of LPS failed to inhibit gastric
motility. The inhibitory action of LPS was observed
immediately after intraperitoneal injection of LPS and
persisted more than 60 min. As demonstrated in Table 1, a
significant inhibition of MI was observed when LPS was
injected at doses of 0.2 mg/kg or more.
To evaluate the mechanisms by which LPS inhibit
gastric motility, effects of cytokines such as IL-1b, -6 or
TNF-a, which are possibly induced by LPS on gastric
motility, were examined. Figure 2a reveals that intraperi-
toneal injection of IL-1b at a dose of 2 lg/kg strongly
suppressed gastric antral motility. The inhibition was
observed for more than 60 min. As demonstrated in
Table 1, intraperitoneal injection of IL-1b decreased MI in
a dose dependent manner. On the other hand, TNF-a at
doses of 2 and 20 lg/kg or IL-6 at doses of 0.2 and 2 lg/kg
failed to change gastric motility as shown in Fig. 2b and
Table 1, suggesting that among tested cytokines, IL-1b
specifically inhibited gastric motility.
Next, to clarify the hypothesis that endogenously released
IL-1 mediates the LPS-induced inhibition of gastric motility,
we examined the effects of IL-1Ra on the LPS-induced
suppression of gastric motility. Intraperitoneal injection of
Fig. 1 Representative
recordings of gastric antral
contractions in rats injected
intraperitoneally with either
saline, 0.002 or 20 mg/kg of
lipopolysaccharide (LPS)
Table 1 Effects of intraperitoneal injection of chemicals on gastric
antral motility in conscious rats
Treatment N %MI
Saline 5 90.9 ± 5.4
LPS (mg/kg)
0.002 4 100.3 ± 10.1
0.2 5 44.3 ± 6.5a
20 7 49.3 ± 7.4a
IL-1b (lg/kg)
0.2 6 76.2 ± 5.4
2 5 33.8 ± 6.6a
TNF-a (lg/kg)
2 6 101.5 ± 14.9
20 7 80.9 ± 5.4
IL-6 (lg/kg)
0.2 4 79.4 ± 6.4
2 7 81.6 ± 12.2
IL-1Ra (mg/kg)
20 5 94.3 ± 15.9
Saline ? LPS (0.2 mg/kg) 7 44.2 ± 9.2
IL-1Ra (20 mg/kg) ? LPS (0.2 mg/kg) 5 96.0 ± 8.8b
Each data represents the mean ± SE
a P \ 0.05, when compared with saline
b P \ 0.05, when compared with saline ? LPS (0.2 mg/kg)
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IL-1Ra at a dose of 20 mg/kg by itself did not change gastric
motility (Fig. 3a; Table 1). In contrast, pretreatment with
IL-1Ra significantly blocked the inhibition of gastric
motility by intraperitoneal LPS at a dose of 0.2 mg/kg as
shown in Fig. 3b and Table 1, suggesting that endogenously
released IL-1 could be involved in the inhibition of gastric
motility by LPS.
Discussion
The present study clearly demonstrated that LPS at doses
of 0.2 mg/kg and more suppressed gastric antral motility in
freely moving conscious rats. Earlier investigators dem-
onstrated that intravenous injection of LPS at a dose of
0.04 mg/kg by itself failed to change gastric pressure but
Fig. 2 Representative
recordings of gastric antral
contractions in rats injected
intraperitoneally with either
IL-1b (a), TNF-a or IL-6 (b)
Fig. 3 Representative
recordings of gastric antral
contractions in rats injected with
IL-1Ra alone (a) or either saline
or IL-1Ra plus intraperitoneal
injection of LPS at a dose of
0.2 mg/kg (b)
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could inhibit the stimulated gastric tone induced by
2-deoxy-D-glucose in urethane-anesthetized rats [12]. In
contrast, Watanabe et al. [13] have shown that gastric
motility detected by force transducers in conscious fasted
rats was stimulated within 2–3 min after intravenous
injection of LPS at a dose of 1 mg/kg injected intrave-
nously, and repetitive contraction waves emerged and
continued for 15–20 min, and then motility was suppressed
for more than 2 h. It was also reported in the study that a
0.3 mg/kg dose of LPS failed to inhibit gastric contractil-
ity. The discrepancy of the effect of LPS on gastric motility
between the present study and the previous studies as
described above might come from the difference of fasted
or fed state, anesthetized or conscious, and/or force trans-
ducers or manometric method. As reported by previous
researchers, LPS potently inhibits gastric emptying. Since
gastric antral motility is deeply involved in the gastric
emptying [16], the present data may suggest that inhibition
of gastric antral motility by LPS in conscious rats con-
tributes to the delayed gastric emptying seen in previous
studies.
LPS causes the release by the host of numerous proin-
flammatory mediators, such as TNF-a, IL-6 and IL-1b
through activation of NF-jB [17]. To clarify the mecha-
nism of how LPS suppresses gastric motility in conscious
rats, we examined the effects of LPS-induced cytokines,
TNF-a, IL-6 or IL-1b on gastric antral contractility. The
present study clearly demonstrated that IL-1b dose-
dependently suppressed gastric antral motility while nei-
ther IL-6 nor TNF-a inhibited gastric motility in freely
moving conscious fed rats. These results suggest that
among inflammatory cytokines, IL-1b is specifically
capable of inhibiting gastric motility.
A couple of reports demonstrated that TNF-a acts in the
brain to suppress gastric tone in anesthetized rats. For
instance, TNF-a injected directly into the dorsal motor
nucleus (DMN) in the medulla oblangata, the cells of ori-
gin innervating the stomach through the vagus nerve [18],
causes a reduction of gastric tone [19]. In addition, con-
tinuous perfusion of the floor of the fourth ventricle with
TNF absorbant construct reversed the inhibition of gastric
motility by LPS [20]. Based upon this evidence, TNF-a
may act in the brain to be involved in the inhibition of
gastric function by LPS. The present study, however,
showed that intraperitoneal injection of TNF-a failed to
change gastric tone, suggesting that gastric motility could
not be changed by circulating TNF-a. These results led us
to speculate that direct application of TNF-a into the brain
might be needed to change gastric motility. Otherwise, the
discrepancy between the evidence by earlier investigators
and our results in this study may come from the difference
of anesthetized or conscious rats. Further studies should be
performed to clarify the issue.
Most previous studies of the effect of IL-1b on gastro-
intestinal motility have concerned the small and large
intestines. For example, Fargeas et al. [21] revealed that
centrally administered IL-1b at a dose of 15 ng potently
stimulated cecocolonic motility in conscious rats. On the
other hand, peripheral injection of IL-1b failed to stimulate
cecocolonic motility, suggesting that IL-1b acts centrally
in the brain to stimulate lower GI motility. With regard to
the effect of IL-1b on gastric motility, a couple of studies
have shown that IL-1b modifies gastric motility in exper-
imental animals. Montuschi et al. [22] demonstrated that
IL-1b is capable of inducing dose-dependent relaxation in
rat gastric fundus strip in vitro, suggesting that IL-1b acts
directly in the stomach to relax gastric smooth muscle.
According to the report by Su¨to¨ et al. [23], IL-1b injected
intracisternally or intravenously dose-dependently
decreased gastric emptying, respectively. The median
effective dose (ED50) was 30-fold lower when IL-1b was
injected intracisternally rather than intravenously, sug-
gesting a site of action of IL-1b should be in the brain.
Thus, it has not been established whether the site of action
of IL-1b is on the brain and/or the stomach. In addition, we
could not find any recordings of gastric contractility in
conscious animals injected with IL-1b. The present study
therefore clearly demonstrated for the first time that IL-1b
potently inhibits gastric contractility in freely moving
conscious rats. Further studies should be needed to clarify
if IL-1b acts in the brain to inhibit gastric tone.
The present study demonstrated that each LPS or IL-1b
strongly inhibited gastric motility in conscious rats. Based
upon the findings, we made a hypothesis that IL-1b
mediates the LPS-induced inhibition of gastric motility. In
the next step, we tried to clarify the hypothesis using an
IL-1Ra.
The action of IL-1 is mediated by two different gene
products, IL-1a and IL-1b [24, 25]. These two cytokines
bind to IL-1 receptor-1 (IL-1R1). The effects of IL-1 are
strictly regulated by naturally occurring inhibitors, such as
IL-1Ra [26]. It has been established that IL-1Ra binds to
IL-1R1 and thus antagonizes biological effects of IL-1
[27]. Anakinra used in this study is a nonglycosylated,
recombinant form of human IL-1Ra that, like endogenous
IL-1Ra, competitively inhibits IL-1 by binding IL-1 R1 and
regulates negatively the IL-1 signaling [28, 29]. In exper-
imental animals, IL-1Ra is effective to antagonize the
influence of IL-1 b [30, 31]. Terrando et al. [30] have
shown that administration of IL-1Ra reduced hippocampal
microgliosis and ameliorated cognitive dysfunction
induced by intraperitoneal injection of LPS in mice, sug-
gesting that IL-1 signaling by LPS may induce microglial
activation in the brain and lead to behavioral abnormality.
Auvin et al. [32] demonstrated that inflammation provoked
by LPS enhanced rapid kindling epileptogenesis in
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immature rat brains. In this model, IL-1Ra was able to
mitigate the augmentation of epileptogenesis enhance by
LPS, suggesting IL-1 signaling may partly mediate the
epileptogenesis by LPS. In the experiments, IL-1Ra at a
dose of 25 mg/kg was administered intraperitoneally to
block the effect of intraperitoneal injection of LPS. Girard
et al. [31] reported that IL-1Ra protected against placental
and neurodevelopmental defects induced by LPS-induced
maternal inflammatory response in rats. In the study,
IL-1Ra at doses of 2–20 mg/kg was used to block the LPS
(0.2 mg/kg)-induced effect in rats. The dose of IL-1Ra
(20 mg/kg) used in the present study was therefore selected
according to the above reports.
As demonstrated in this study, IL-1Ra drastically blocked
the LPS-induced inhibition of gastric motility while IL-1Ra
by itself failed to change gastric motility, suggesting for the
first time that IL-1 mediates the LPS-induced inhibition of
gastric motility. Because little is known whether endoge-
nously released IL-1 is indeed implicated in the gastroin-
testinal functions, the present study provides a novel
evidence that endogenously released IL-1 indeed plays a key
role in the regulation of gastrointestinal functions.
IL-1Ra has been tested clinically in patients with rheu-
matoid arthritis, with small effect [33]. On the other hand,
beneficial effects by IL-1Ra were observed in patients with
cryopyrinopathie, which is known as autoinflammatory con-
ditions closely associated with excessive IL-1 signaling [26].
IL-1Ra has also been reported to be effective in Schnizler
syndrome, systemic-onset juvenile idiopathic arthritis and
adult Still disease [26]. Furthermore, recent studies have
demonstrated that IL-1 targeting is efficacious in type 2
diabetes [34] and gout [35]. In addition to the previous find-
ings, the present evidence that IL-1Ra blocks the LPS-
induced change of gastric motility in conscious rats may
contribute to develop a novel therapeutic approach to improve
gastrointestinal motility disturbance under septic conditions.
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